TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREVALENCE OF COLON CANCER IN INDIA AND OTHER DEVELOPING NATIONS
4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
4.2.3 INCREASING SEDENTARY LIFESTYLE AND PHYSICAL INACTIVITY
4.3 RESTRAINTS
4.3.1 SIDE EFFECTS ASSOCIATED WITH PEG 3500
4.3.2 INCREASING PREFERENCE FOR ORGANIC ALTERNATIVES
4.4 OPPORTUNITIES
4.4.1 ENTERING DEVELOPING MARKETS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING & SALES
5.1.5 POST-SALES REVIEW/MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL PEG 3350 MARKET
5.3.1 IMPACT ON DEMAND
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON MARKET PLAYERS
6 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 POWDER
6.3 BOWEL PREPARATION KIT
7 GLOBAL PEG 3350 MARKET, BY AGE
7.1 OVERVIEW
7.2 PEDIATRIC
7.3 ADULT
7.4 GERIATRIC
8 GLOBAL PEG 3350 MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CONSTIPATION
8.3 MEDICAL TESTS
8.3.1 COLONOSCOPY
8.3.2 BARIUM ENEMA X-RAY EXAMINATION
8.4 SURGERY
9 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 ONLINE PHARMACY
9.3 OFFLINE PHARMACY
10 GLOBAL PEG 3350 MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL PEG 3350 MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL PEG 3350 MARKET
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 PRODUCT LAUNCH/PRODUCT APPROVAL
12 COMPANY PROFILES
12.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL ANALYSIS
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIES
12.2 LGM PHARMA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 MCKESSON CORPORATION
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 SISCO RESEARCH LABORATORIES PVT. LTD.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 BASF SE
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 MERCK KGAA
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 BAYER AG
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 LUPIN PHARMACEUTICALS, INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 BRECKENRIDGE PHARMACEUTICAL, INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 PENDOPHARM
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 4 GLOBAL PEG 3350 MARKET, FOR POWDER, BY REGION, 2018–2030 (USD MILLION)
TABLE 5 GLOBAL PEG 3350 MARKET, FOR BOWEL PREPARATION KIT, BY REGION, 2018–2030 (USD MILLION)
TABLE 6 GLOBAL PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 7 GLOBAL PEG 3350 MARKET, FOR PEDIATRIC, BY REGION, 2018–2030 (USD MILLION)
TABLE 8 GLOBAL PEG 3350 MARKET, FOR ADULT, BY REGION, 2018–2030 (USD MILLION)
TABLE 9 GLOBAL PEG 3350 MARKET, FOR GERIATRIC, BY REGION, 2018–2030 (USD MILLION)
TABLE 10 GLOBAL PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 11 GLOBAL PEG 3350 MARKET, FOR CONSTIPATION, BY REGION, 2018–2030 (USD MILLION)
TABLE 12 GLOBAL PEG 3350 MARKET, FOR MEDICAL TESTS, BY REGION, 2018–2030 (USD MILLION)
TABLE 13 GLOBAL PEG 3350 MARKET, FOR COLONOSCOPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 14 GLOBAL PEG 3350 MARKET, FOR BARIUM ENEMA X-RAY EXAMINATION, BY REGION, 2018–2030 (USD MILLION)
TABLE 15 GLOBAL PEG 3350 MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)
TABLE 16 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 17 GLOBAL PEG 3350 MARKET, FOR ONLINE PHARMACY, BY REGION, 2018–2030 (USD MILLION)
TABLE 18 GLOBAL PEG 3350 MARKET, FOR OFFLINE PHARMACY, BY REGION, 2018–2030 (USD MILLION)
TABLE 19 GLOBAL: PEG 3350 MARKET, BY REGION, 2018–2030 (USD MILLION)
TABLE 20 NORTH AMERICA: PEG 3350 MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 21 NORTH AMERICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 22 NORTH AMERICA: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 23 NORTH AMERICA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 24 NORTH AMERICA: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2018–2030 (USD MILLION)
TABLE 25 NORTH AMERICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 26 US: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 27 US: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 28 US: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 29 US: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2018–2030 (USD MILLION)
TABLE 30 US: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 31 CANADA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 32 CANADA: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 33 CANADA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 34 CANADA: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2018–2030 (USD MILLION)
TABLE 35 CANADA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 36 EUROPE: PEG 3350 MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 37 EUROPE: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 38 EUROPE: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 39 EUROPE: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 40 EUROPE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 41 EUROPE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 42 GERMANY: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 43 GERMANY: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 44 GERMANY: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 45 GERMANY: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 46 GERMANY: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 47 FRANCE: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 48 FRANCE: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 49 FRANCE: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 50 FRANCE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 51 FRANCE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 52 UK: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 53 UK: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 54 UK: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 55 UK: PEG 3350 MARKET, FOR MEDICAL TESTS BY TYPE, 2018–2030 (USD MILLION)
TABLE 56 UK: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 57 ITALY: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 58 ITALY: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 59 ITALY: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 60 ITALY: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 61 ITALY: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 62 SPAIN: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 63 SPAIN: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 64 SPAIN: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 65 SPAIN: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 66 SPAIN: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 67 REST OF EUROPE: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 68 REST OF EUROPE: PEG 3350 MARKET, BY AGE, 2018–2030 (USD MILLION)
TABLE 69 REST OF EUROPE: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 70 REST OF EUROPE: PEG 3350 MARKET, FOR MEDICAL TESTS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 71 REST OF EUROPE: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC: PEG 3350 MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 78 CHINA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 79 CHINA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 80 CHINA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 81 CHINA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 82 CHINA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 83 INDIA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 84 INDIA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 85 INDIA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 86 INDIA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 87 INDIA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 88 JAPAN: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 89 JAPAN: PEG 3350 MARKET, BY AGE, 2018-2030(USD MILLION) (USD MILLION)
TABLE 90 JAPAN: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 91 JAPAN: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 92 JAPAN: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 93 SOUTH KOREA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 94 SOUTH KOREA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 95 SOUTH KOREA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 96 SOUTH KOREA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 97 SOUTH KOREA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 98 AUSTRALIA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 99 AUSTRALIA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 100 AUSTRALIA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 101 AUSTRALIA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 102 AUSTRALIA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 103 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 104 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 105 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 106 REST OF ASIA PACIFIC: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 107 REST OF ASIA PACIFIC: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 108 REST OF THE WORLD: PEG 3350 MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109 REST OF THE WORLD: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 110 REST OF THE WORLD: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 111 REST OF THE WORLD: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 112 REST OF THE WORLD: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 113 REST OF THE WORLD: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 114 MIDDLE EAST: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 115 MIDDLE EAST: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 116 MIDDLE EAST: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 117 MIDDLE EAST: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 118 MIDDLE EAST: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 119 AFRICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 120 AFRICA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 121 AFRICA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 122 AFRICA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 123 AFRICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 124 LATIN AMERICA: PEG 3350 MARKET, BY PRODUCT TYPE, 2018–2030 (USD MILLION)
TABLE 125 LATIN AMERICA: PEG 3350 MARKET, BY AGE, 2018-2030 (USD MILLION)
TABLE 126 LATIN AMERICA: PEG 3350 MARKET, BY APPLICATION, 2018–2030 (USD MILLION)
TABLE 127 LATIN AMERICA: PEG 3350 MARKET FOR MEDICAL TEST, BY TYPE, 2018–2030 (USD MILLION)
TABLE 128 LATIN AMERICA: PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)
TABLE 129 MAJOR PLAYERS IN THE GLOBAL PEG 3350 MARKET
TABLE 130 MOST ACTIVE PLAYER IN THE GLOBAL PEG 3350 MARKET
TABLE 131 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 132 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES OFFERED
TABLE 133 LGM PHARMA: PRODUCTS/SERVICES OFFERED
TABLE 134 MCKESSON CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 135 SISCO RESEARCH LABORATORIES PVT. LTD.: PRODUCTS/SERVICES OFFERED
TABLE 136 BASF SE: PRODUCTS/SERVICES OFFERED
TABLE 137 MERCK KGAA: PRODUCTS OFFERED
TABLE 138 BAYER AG: PRODUCTS OFFERED
TABLE 139 BAYER AG: KEY DEVELOPMENTS
TABLE 140 LUPIN PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 141 BRECKENRIDGE PHARMACEUTICAL, INC.: PRODUCTS OFFERED
TABLE 142 PENDOPHARM: PRODUCTS OFFERED
TABLE 143 PENDOPHARM: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL PEG 3350 MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PEG 3350 MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL PEG 3350 MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEG 3350 MARKET
FIGURE 9 GLOBAL PEG 3350 MARKET, BY PRODUCT TYPE, 2021 & 2030 (USD MILLION)
FIGURE 10 GLOBAL PEG 3350 MARKET, BY AGE, 2021 & 2030 (USD MILLION)
FIGURE 11 GLOBAL PEG 3350 MARKET, BY APPLICATION, 2021 & 2030 (USD MILLION)
FIGURE 12 GLOBAL PEG 3350 MARKET, BY DISTRIBUTION CHANNEL, 2021 & 2030 (USD MILLION)
FIGURE 13 GLOBAL: PEG 3350 MARKET, BY REGION 2021 & 2030 (USD MILLION)
FIGURE 14 GLOBAL: PEG 3350 MARKET SHARE (%), BY REGION, 2021
FIGURE 15 NORTH AMERICA: PEG 3350 MARKET SHARE (%), BY COUNTRY 2021
FIGURE 16 EUROPE: PEG 3350 MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 17 ASIA-PACIFIC: PEG 3350 MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 18 REST OF THE WORLD: PEG 3350 MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL PEG 3350 MARKET
FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 MCKESSON CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 MCKESSON CORPORATION: SWOT ANALYSIS
FIGURE 24 BASF SE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 BASF SE: SWOT ANALYSIS
FIGURE 26 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 MERCK KGAA: SWOT ANALYSIS
FIGURE 28 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 BAYER AG: SWOT ANALYSIS
FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS